Alström Syndrome in the News

Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity

  • Further Improvements Observed in Bardet-Biedl Syndrome Patients; Initial Proof-of-Concept Data in Alström Syndrome Demonstrates Significant Weight Loss and Decreased Hunger
  • Rhythm Plans to Initiate Combined Pivotal Phase 3 Trial in Bardet-Biedl Syndrome and Alström Syndrome in 2018
  • Preliminary Data in Patients with POMC and Other MC4 Pathway Heterozygous Deficiency Obesities and POMC Epigenetic Disorders Demonstrate Clinically-Meaningful Reductions in Weight and Hunger

Read the full press release on Rhythm Pharmaceuticals’ website.

This entry was posted in ASI News by Tony Jackson. Bookmark the permalink.

About Tony Jackson

Originally from the fine state of GA, I moved to Maine in 2000, and have been working with Jan and Robin to one degree or another for several years. As the resident Tech Monkey for ASI, you'll see me attached to web stuff and technical challenges ASI and those they support may face.

Leave a Reply